New interim data on long-term efficacy and safety data up to 7.5 years post-dosing of Zolgensma.
Novartis announced new long-term data for Zolgensma® (onasemnogene abeparvovec).
The latest data from two Long-Term Follow-Up (LTFU) studies, LT-001 and LT-002, show the continued efficacy and durability of Zolgensma across a range of patient populations, with an overall benefit-risk profile that remains favourable, with treated children maintaining motor milestones up to 7.5 years post-dosing.